US FDA calls Avodart TV commercial misleading
This article was originally published in Scrip
Executive Summary
A direct-to-consumer TV commercial for GlaxoSmithKline's benign prostatic hyperplasia treatment Avodart (dutasteride) presents misleading comparative claims and overstates its efficacy, the US FDA has said.